NASDAQ:IPA - CA45257F2008 - Common Stock
The current stock price of IPA is 2.07 USD. In the past month the price increased by 14.36%. In the past year, price increased by 209.19%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 22.5 | 186.01B | ||
DHR | DANAHER CORP | 26.59 | 143.36B | ||
A | AGILENT TECHNOLOGIES INC | 23.62 | 36.57B | ||
IQV | IQVIA HOLDINGS INC | 16.36 | 31.91B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 31.92 | 26.90B | ||
WAT | WATERS CORP | 25.05 | 18.23B | ||
WST | WEST PHARMACEUTICAL SERVICES | 36.02 | 18.03B | ||
ILMN | ILLUMINA INC | 23.78 | 15.21B | ||
TEM | TEMPUS AI INC | N/A | 13.83B | ||
MEDP | MEDPACE HOLDINGS INC | 36.21 | 13.68B | ||
ICLR | ICON PLC | 13.22 | 13.60B | ||
QGEN | QIAGEN N.V. | 20.23 | 10.31B |
ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The company is headquartered in Austin, Texas. The company is advancing Bio-Native AI at the intersection of biology and computation. Its LENSai and HYFT platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. The core of its operations encompasses a diverse suite of proprietary technologies that aid in the exploration, discovery, and development of novel drugs and biologics. Integrated within its wet lab infrastructure is a diverse array of in silico technologies. As an end-to-end service provider of antibody discovery and development, its computational methodologies allow the Company to perform detailed and comprehensive evaluations across various stages of biologic discovery and development. The company is involved in antibody characterization studies, which encompass affinity measurements, epitope landscape profiling, and others.
IMMUNOPRECISE ANTIBODIES LTD
Industrious 823 Congress Ave Suite 300
Austin TEXAS US
Employees: 87
Phone: 16048060626
The current stock price of IPA is 2.07 USD. The price increased by 7.25% in the last trading session.
The exchange symbol of IMMUNOPRECISE ANTIBODIES LTD is IPA and it is listed on the Nasdaq exchange.
IPA stock is listed on the Nasdaq exchange.
6 analysts have analysed IPA and the average price target is 5.1 USD. This implies a price increase of 146.38% is expected in the next year compared to the current price of 2.07. Check the IMMUNOPRECISE ANTIBODIES LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a market capitalization of 95.53M USD. This makes IPA a Micro Cap stock.
IMMUNOPRECISE ANTIBODIES LTD (IPA) currently has 87 employees.
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a support level at 1.92. Check the full technical report for a detailed analysis of IPA support and resistance levels.
The Revenue of IMMUNOPRECISE ANTIBODIES LTD (IPA) is expected to grow by 13.46% in the next year. Check the estimates tab for more information on the IPA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IPA does not pay a dividend.
IMMUNOPRECISE ANTIBODIES LTD (IPA) will report earnings on 2025-09-11.
IMMUNOPRECISE ANTIBODIES LTD (IPA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).
The outstanding short interest for IMMUNOPRECISE ANTIBODIES LTD (IPA) is 1.03% of its float. Check the ownership tab for more information on the IPA short interest.
ChartMill assigns a technical rating of 9 / 10 to IPA. When comparing the yearly performance of all stocks, IPA is one of the better performing stocks in the market, outperforming 98.69% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to IPA. IPA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months IPA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 34.78% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -68.03% | ||
ROE | -127.97% | ||
Debt/Equity | 0.49 |
6 analysts have analysed IPA and the average price target is 5.1 USD. This implies a price increase of 146.38% is expected in the next year compared to the current price of 2.07.
For the next year, analysts expect an EPS growth of 49.5% and a revenue growth 13.46% for IPA